Results 81 to 90 of about 595 (138)
Acute subdural haemorrhage in a warfarin user following leech bite: Clinical note and review. [PDF]
Curr J NeurolDeshmukh AS +4 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Thrombosis Research, 1990
The usability of recombinant hirudin as anticoagulant agent in haemodialysis was studied in nephrectomized dogs. To this end, we examined the capability of recombinant hirudin to penetrate the membranes of different capillary dialyzers used. Furthermore we investigated the pharmacokinetic behaviour of recombinant hirudin in nephrectomized dogs as well ...
E, Bucha, F, Markwardt, G, Nowak
openaire +2 more sources
The usability of recombinant hirudin as anticoagulant agent in haemodialysis was studied in nephrectomized dogs. To this end, we examined the capability of recombinant hirudin to penetrate the membranes of different capillary dialyzers used. Furthermore we investigated the pharmacokinetic behaviour of recombinant hirudin in nephrectomized dogs as well ...
E, Bucha, F, Markwardt, G, Nowak
openaire +2 more sources
Hirudin and hirudin analogues as new anticoagulant agents
Current Opinion in Hematology, 1995Recombinant hirudin and hirudin analogues constitute interesting new antithrombotic agents that have distinct advantages over heparin. These agents specifically inhibit thrombin and all of its actions and also suppress further thrombin generation. As opposed to unfractionated heparin, hirudin and hirulog effectively suppress clot-bound thrombin, making
G F, Pineo, R D, Hull
openaire +2 more sources
Seminars in Thrombosis and Hemostasis, 1997
Recombinant (r-) hirudins and PEG-hirudin are currently tested for anticoagulant therapy. For their concentration measurement, radioimmunoassay and HPLC methods are available. The separation of r- and PEG-hirudin is currently performed by HPLC. However, the sensitivity of the method is low. Capillary electrophoresis is a rapid, selective technique that
R, Malsch, A, Timmermann, J, Harenberg
openaire +2 more sources
Recombinant (r-) hirudins and PEG-hirudin are currently tested for anticoagulant therapy. For their concentration measurement, radioimmunoassay and HPLC methods are available. The separation of r- and PEG-hirudin is currently performed by HPLC. However, the sensitivity of the method is low. Capillary electrophoresis is a rapid, selective technique that
R, Malsch, A, Timmermann, J, Harenberg
openaire +2 more sources
Australian and New Zealand Journal of Medicine, 1993
Abstract:A brief outline is presented of a proposed trial of Hirulog versus heparin after thrombolytic therapy with streptokinase (SK). The lower patency rates achieved with SK compared with tissue plasminogen activator (t‐PA) suggest that a potent thrombin specific agent may be more important for SK than for t‐PA therapy.
openaire +2 more sources
Abstract:A brief outline is presented of a proposed trial of Hirulog versus heparin after thrombolytic therapy with streptokinase (SK). The lower patency rates achieved with SK compared with tissue plasminogen activator (t‐PA) suggest that a potent thrombin specific agent may be more important for SK than for t‐PA therapy.
openaire +2 more sources
[Hirudin and hirudin fragments].
Annales de cardiologie et d'angeiologie, 1993Hirudin is a potent and specific thrombin inhibitor: compared with heparin thrombin inhibition occurs directly and does not require the presence of plasma cofactors. Recombinant hirudin is well tolerated in animals and in healthy volunteers. Its clearance half-life after IV administration range from 1 to 2 hours and its bioavailability after ...
A, Deschamps, M, Samama
openaire +1 more source
Inpharma Weekly, 1993
Hirudin is a direct thrombin inhibitor derived from leeches. Recombinant forms of hirudin are under development by a number of manufacturers, the most advanced of which are undergoing phase II clinical trials. Ciba-Geigy's desulfatohirudin [CGP 39393] and Hoechst's HBW 023 have been the agents used in a number of clinical trials to date.
openaire +2 more sources
Hirudin is a direct thrombin inhibitor derived from leeches. Recombinant forms of hirudin are under development by a number of manufacturers, the most advanced of which are undergoing phase II clinical trials. Ciba-Geigy's desulfatohirudin [CGP 39393] and Hoechst's HBW 023 have been the agents used in a number of clinical trials to date.
openaire +2 more sources
Use of fragments of hirudin to investigate thrombin‐hirudin interaction
European Journal of Biochemistry, 1990Site‐directed mutagenesis was used to create hirudin in which Asn52 was replaced by methionine. Cyanogen bromide cleavage at this unique methionine resulted in two fragments. These fragments have been used to study the kinetic mechanism of the inhibition of thrombin by hirudin and to identify areas of the two molecules which interact with each other ...
Dennis S +3 more
openaire +3 more sources
Thrombin Inhibition by Hirudin: How Hirudin Inhibits Thrombin
Haemostasis, 2009In addition to its classical active-site regions (catalytic site and adjacent regions), α-thrombin has a unique anion-binding exosite, which is functionally independent of the catalytic site and is involved in fibrin(ogen) recognition. This exosite also accounts for adhesion to negatively charged surfaces (e.g., glass), binding to cell surfaces, and ...
J W, Fenton +3 more
openaire +2 more sources